<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046849</url>
  </required_header>
  <id_info>
    <org_study_id>HDLS201701</org_study_id>
    <nct_id>NCT03046849</nct_id>
  </id_info>
  <brief_title>Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome Criteria</brief_title>
  <official_title>Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer Patients Meeting Chinese Lynch Syndrome Criteria: An Open-label and Multi-center Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the proportion of patients diagnosed with Lynch&#xD;
      syndrome in colorectal cacner patients meeting Chinese Lynch syndrome criteria. Besides, this&#xD;
      study is aimed to analyze the clinical characteristics and germline mutation of Lynch&#xD;
      syndrome in Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Detect germline mutation (by next-generation squencing) in probands.&#xD;
&#xD;
        2. Verify the germline mutation in blood relatives whose proband has known germline&#xD;
           mutation(s).&#xD;
&#xD;
        3. Analyze the test data with clinical and family information. Diagnose Lynch syndrome in&#xD;
           the included population.&#xD;
&#xD;
        4. Analyze the clinical characteristics and germline mutation of Lynch syndrome in Chinese&#xD;
           population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Actual">February 26, 2019</completion_date>
  <primary_completion_date type="Actual">February 26, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathogenic germline mutation</measure>
    <time_frame>Upon completion of study, on average 2 years.</time_frame>
    <description>Pathogenic germline mutation using next-generation sequencing with a targeted panel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variant of uncertain significance of germline mutation</measure>
    <time_frame>Upon completion of study, on average 2 years.</time_frame>
    <description>Variant of uncertain significance using next-generation sequencing with a targeted panel.</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Lynch Syndrome</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>next-generation sequencing</intervention_name>
    <description>Use next-generation sequencing to test germline mutation.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The probands will be selected from colorectal cancer patients meeting Chinese Lynch&#xD;
        syndrome criteria. The blood relatives verifying germline mutation will be selected from&#xD;
        whose proband has germline mutation(s).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For probands, the inclusion criteria： all of the following three points should be&#xD;
        satisfied:&#xD;
&#xD;
          1. One of the colorectal cancer patients from families meeting Chinese Lynch syndrome&#xD;
             criteria.&#xD;
&#xD;
             Chinese Lynch syndrome criteria:&#xD;
&#xD;
             In a pedigree, there were at least 2 patients with histological-proven colorectal&#xD;
             cancer, and among these, at least two patients are first-degree relatives of each&#xD;
             other. Besides, any one of the following three points should be satisfied in the&#xD;
             pedigree:&#xD;
&#xD;
             A. at least one patients with multiple primary colorectal carcinoma/adenoma, either&#xD;
             synchronously or metachronously.&#xD;
&#xD;
             B. at least one colorectal cancer diagnosed before 50 years old. C. in the pedigree,&#xD;
             at least one patient diagnosed with other Lynch syndrome associated cancer (ie,&#xD;
             gastric, endometrial, small bowel, ureter, or renal-pelvic, ovarian and hepatobiliary&#xD;
             cancers).&#xD;
&#xD;
          2. With sufficient blood to test;&#xD;
&#xD;
          3. Agree to provide basic information, clinical information and family history of cancer&#xD;
             information.&#xD;
&#xD;
        For probands, the exclusion criteria:&#xD;
&#xD;
        With at least one blood relative with known pathogenic germline mutation(s).&#xD;
&#xD;
        For blood relatives verifying germline mutation, the inclusion criteria： all of the&#xD;
        following three points should be satisfied:&#xD;
&#xD;
          1. First- to second-degree blood relatives of probands with germline mutation(s).&#xD;
&#xD;
          2. With sufficient blood to test.&#xD;
&#xD;
          3. Agree to provide basic information, clinical information and family history of cancer&#xD;
             information.&#xD;
&#xD;
        For blood relatives verifying germline mutation, the exclusion criteria:&#xD;
&#xD;
        Blood relatives who refuse to test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Yuan, Ph.D, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>332001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejinag</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</investigator_affiliation>
    <investigator_full_name>Ying Yuan, MD</investigator_full_name>
    <investigator_title>Professor, Department of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Lynch Syndrome</keyword>
  <keyword>next-generation sequencing</keyword>
  <keyword>germline mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

